Detalhe da pesquisa
1.
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial.
Oncologist
; 28(1): 23-32, 2023 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36239405
2.
SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA.
Future Oncol
; 2022 Oct 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36200668
3.
Trajectories of alcohol consumption during life and the risk of developing breast cancer.
Br J Cancer
; 125(8): 1168-1176, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34483338
4.
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol
; 21(1): 33-43, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31838010
5.
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.
Breast Cancer Res
; 22(1): 120, 2020 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33138866
6.
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 19(1): 127-138, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29158011
7.
Physical activity and breast cancer risk by pathological subtype.
Gynecol Oncol
; 144(3): 577-585, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28057355
8.
SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.
Breast Cancer Res Treat
; 154(2): 351-7, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26536871
9.
Efficacy and safety of neoadjuvant chemotherapy with concurrent liposomal-encapsulated doxorubicin, paclitaxel and trastuzumab for human epidermal growth factor receptor 2-positive breast cancer in clinical practice.
Int J Clin Oncol
; 20(3): 480-9, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25011497
10.
Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial.
BMC Med
; 17(1): 8, 2019 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30621698
11.
Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management.
Clin Transl Oncol
; 2024 Feb 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38336982
12.
Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy.
NPJ Breast Cancer
; 10(1): 20, 2024 Mar 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38448600
13.
Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis.
Breast Cancer Res
; 15(6): R105, 2013 Nov 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-24192331
14.
Observational study of HR+/HER2- metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS).
Clin Transl Oncol
; 25(10): 2950-2959, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37029241
15.
HOPE (SOLTI-1903) breast cancer study: real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with locally advanced or metastatic breast cancer.
Front Oncol
; 13: 1151496, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37188177
16.
Oncolytic viruses: A new immunotherapeutic approach for breast cancer treatment?
Cancer Treat Rev
; 106: 102392, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35436729
17.
Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial.
Eur J Cancer
; 174: 232-242, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36067616
18.
The role of CDK4/6 inhibitors in early breast cancer.
Breast
; 58: 160-169, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34087775
19.
Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy.
EBioMedicine
; 69: 103451, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34161883
20.
Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy.
Clin Cancer Res
; 27(11): 3116-3125, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33632929